Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTREXION THERAPEUTICS CORPORATION

(CNTX)
 SummaryQuotesNewsCompanyFinancials 
Estimated financial data (e) (USD)
Sales 2017 - - -
Net income 2017 -24,6 M - -
Net cash position 2017 58,7 M - -
P/E ratio 2017 -
Yield 2017 -
Sales 2018 - - -
Net income 2018 -39,0 M - -
Net cash position 2018 23,8 M - -
P/E ratio 2018 -
Yield 2018 -
Capitalization - - -
EV / Sales 2017 -
EV / Sales 2018 -
Nbr of Employees 24
Free-Float -
More Financials
Company
Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies... 
More about the company
All news about CENTREXION THERAPEUTICS CORPORATION
01/26Centrexion Therapeutics Corporation announced that it has received $13.5 mill..
CI
01/12Centrexion Therapeutics Corporation announced that it expects to receive $13...
CI
2020Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset M..
GL
2020Centrexion Therapeutics Corporation announced that it has received funding fr..
CI
2020Centrexion Therapeutics Corporation has withdrawn its IPO.
CI
2019Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Pate..
GL
2019Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 Am..
GL
2019Centrexion Corp Reports Earnings Results for the Half Year Ended June 30, 201..
CI
2019Centrexion Therapeutics Corporation Auditor Raises 'Going Concern' Doubt
CI
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY..
GL
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY..
CI
2019CORRECTION - Centrexion Therapeutics
GL
2019Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Pre..
GL
2019Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Pre..
CI
2019Centrexion Therapeutics to Present New Positive Clinical Trial Results on Str..
GL
More news
News in other languages on CENTREXION THERAPEUTICS CORPORATION

- No features available -

More news
Chart CENTREXION THERAPEUTICS CORPORATION
Duration : Period :
Centrexion Therapeutics Corporation Technical Analysis Chart | CNTX | US15643W1009 | MarketScreener
Income Statement Evolution
Managers and Directors
Jeffrey B. Kindler Chief Executive Officer & Director
James N. Campbell President, Director & Chief Scientific Officer
Brian Nicholas Harvey Chief Financial Officer, Treasurer & Executive VP
Sol J. Barer Chairman
Randall M. Stevens Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CENTREXION THERAPEUTICS CORPORATION0.00%0
MODERNA, INC.315.87%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.44.30%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-13.16%27 670